[
  {
    "ts": null,
    "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
    "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
    "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757962258,
      "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
      "id": 136767795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428756484/image_1428756484.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
      "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence",
    "summary": "Although healthcare juggernaut Eli Lilly has struggled for momentum this year, the latest unusual options activity for LLY stock could point to potential upside.",
    "url": "https://finnhub.io/api/news?id=517941f77a87346f233b53eceb57f7f19cda9cbc471742e51add844acbd2ce89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757961002,
      "headline": "Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence",
      "id": 136768081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Although healthcare juggernaut Eli Lilly has struggled for momentum this year, the latest unusual options activity for LLY stock could point to potential upside.",
      "url": "https://finnhub.io/api/news?id=517941f77a87346f233b53eceb57f7f19cda9cbc471742e51add844acbd2ce89"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Popped Today",
    "summary": "A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.",
    "url": "https://finnhub.io/api/news?id=44a4bc5535f2a0f09f5dd1b34cab8b983730b17eb0f983a800d76b3f4828c9cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757954086,
      "headline": "Why Novo Nordisk Stock Popped Today",
      "id": 136765830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.",
      "url": "https://finnhub.io/api/news?id=44a4bc5535f2a0f09f5dd1b34cab8b983730b17eb0f983a800d76b3f4828c9cf"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?",
    "summary": "Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.",
    "url": "https://finnhub.io/api/news?id=644e497a5523ff99a16bbc092ba0211d21e796e62010e618eca66d01e4a65977",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757952480,
      "headline": "Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?",
      "id": 136765832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.",
      "url": "https://finnhub.io/api/news?id=644e497a5523ff99a16bbc092ba0211d21e796e62010e618eca66d01e4a65977"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.",
    "summary": "Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.",
    "url": "https://finnhub.io/api/news?id=135343b43df07e3d8bcc90cb5e74ead2903e49bb5cecb29858d48c1965c20ced",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757951400,
      "headline": "Novo Nordisk Stock Rises. Its Diabetes Pill Cleared a Key Hurdle.",
      "id": 136765833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.",
      "url": "https://finnhub.io/api/news?id=135343b43df07e3d8bcc90cb5e74ead2903e49bb5cecb29858d48c1965c20ced"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery",
    "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company announced the launch of an artificial intelligence and machine learning platform. TuneLab is the platform that consists of AI models and proprietary data obtained at a cost of more than $1 billion. […]",
    "url": "https://finnhub.io/api/news?id=c29254816f29093f59bc1c5ba15da340d8dd2cd5344c6fb32040f2f7480370b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757945015,
      "headline": "Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery",
      "id": 136749495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co. (NYSE:LLY) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company announced the launch of an artificial intelligence and machine learning platform. TuneLab is the platform that consists of AI models and proprietary data obtained at a cost of more than $1 billion. […]",
      "url": "https://finnhub.io/api/news?id=c29254816f29093f59bc1c5ba15da340d8dd2cd5344c6fb32040f2f7480370b2"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?",
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=1a652aa1211ef3d89412a59c4b17de6dabcc27d2f5e1e0d15349d85595b31e53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944804,
      "headline": "Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?",
      "id": 136765834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=1a652aa1211ef3d89412a59c4b17de6dabcc27d2f5e1e0d15349d85595b31e53"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly",
    "summary": "Novo Gains Ground in Obesity Drug Race With New Semaglutide Data",
    "url": "https://finnhub.io/api/news?id=fc5f703e69e0b943dbabe4c06cde2d9abe18b7afdc011cbc2e9f76be8ba01d4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757943862,
      "headline": "Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly",
      "id": 136749496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Gains Ground in Obesity Drug Race With New Semaglutide Data",
      "url": "https://finnhub.io/api/news?id=fc5f703e69e0b943dbabe4c06cde2d9abe18b7afdc011cbc2e9f76be8ba01d4a"
    }
  },
  {
    "ts": null,
    "headline": "Three Stocks Estimated To Be Trading Below Intrinsic Value By Up To 34.7 Percent",
    "summary": "As the U.S. stock market navigates a landscape marked by mixed index performances and anticipation of interest rate decisions, investors are keenly observing sectors that could benefit from potential economic shifts. In this environment, identifying stocks trading below their intrinsic value can offer opportunities for those looking to capitalize on underappreciated assets, particularly as market conditions evolve.",
    "url": "https://finnhub.io/api/news?id=f863eeb8275cd61465fc4505b6a371575ea0eb2264dfc35dafa3ee173fa289f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757939890,
      "headline": "Three Stocks Estimated To Be Trading Below Intrinsic Value By Up To 34.7 Percent",
      "id": 136749497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the U.S. stock market navigates a landscape marked by mixed index performances and anticipation of interest rate decisions, investors are keenly observing sectors that could benefit from potential economic shifts. In this environment, identifying stocks trading below their intrinsic value can offer opportunities for those looking to capitalize on underappreciated assets, particularly as market conditions evolve.",
      "url": "https://finnhub.io/api/news?id=f863eeb8275cd61465fc4505b6a371575ea0eb2264dfc35dafa3ee173fa289f5"
    }
  },
  {
    "ts": null,
    "headline": "How Bad Is This Sector’s Health Scare?",
    "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
    "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937307,
      "headline": "How Bad Is This Sector’s Health Scare?",
      "id": 136749580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
      "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Novo Nordisk's Wegovy Delivers Increased Weight Loss in Triple-Dose Trials",
    "summary": "Novo Nordisk's (NVO) obesity treatment drug Wegovy led to increased weight loss in patients during t",
    "url": "https://finnhub.io/api/news?id=500e2676aadece2acfeb2549bf5a4a951b145d68854609e777dc26141bb5ca5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757935568,
      "headline": "Market Chatter: Novo Nordisk's Wegovy Delivers Increased Weight Loss in Triple-Dose Trials",
      "id": 136749498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's (NVO) obesity treatment drug Wegovy led to increased weight loss in patients during t",
      "url": "https://finnhub.io/api/news?id=500e2676aadece2acfeb2549bf5a4a951b145d68854609e777dc26141bb5ca5e"
    }
  },
  {
    "ts": null,
    "headline": "1 Stock That Should Be in Every Investor's Portfolio",
    "summary": "Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.",
    "url": "https://finnhub.io/api/news?id=f9e4ff6fd3f127ed77fe0ac9aac1cfa121e699f8b10b6abf68e04731d462a332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757934900,
      "headline": "1 Stock That Should Be in Every Investor's Portfolio",
      "id": 136749499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.",
      "url": "https://finnhub.io/api/news?id=f9e4ff6fd3f127ed77fe0ac9aac1cfa121e699f8b10b6abf68e04731d462a332"
    }
  }
]